Skip to main content Skip to main content
Go to homepage

Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Description:

For complete study information, please view the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

 

Study Status:
Closed
Study Sponsor:

Children’s Oncology Group

Full IRB Study Title:
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
IRB Study ID:
1118157-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.